Answers are grounded in this paper and cite their sources.
Brief Review of the Data D iabetic macular oedema (DMO) affects up to 20 million people worldwide and is a leading cause of blindness in working-age adults in developed nations.Intravitreal therapies have replaced macular laser over the past decade as the modality of choice for centreinvolving DMO.Anti-vascular endothelial growth factor (anti-VEGF) agents are the current first-line therapy for DMO due to their proven efficacy and side-effect profile.Intravitreal steroids also have proven efficacy and are typically reserved for certain population subsets such as those who have an inadequate response to anti-VEGF agents, pseudophakics or those about to undergo cataract surgery, and in some cases, social or logistical reasons.Of the steroid agents, the dexamethasone intravitreal implant has the most acceptable sideeffect profile and is most commonly utilised.This shift in the way DMO is treated has led to changing patient demographics and an important aspect of future studies will be identifying how to better stratify patients to receive the most appropriate treatment.
No takes yet. Share an insight, caveat, or question.
Kirk et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: